New psychoactive substances and the Internet: current situations and issues
Tendances n°84, OFDT, 8 p.
The terms 'new psychoactive substances' (NPS) and 'new synthetic substances' appeared in 2008 to describe a range of diverse substances that mimic the effects of various illegal substances (ecstasy, amphetamines, cocaine, cannabis, etc.). Other terms used such as designer drugs, research chemicals (RC) and legal highs respectively allude to their imitative aspect, the fact that they are artificially synthesised and their legal status.
The molecular structure of all these new psychoactive substances is close to that of the product they are "copying" without being identical. This circumvents the legislation, at least in the short term, because the new products are not immediately classified as narcotics as soon as they are developed.
With the number of such substances continuously growing and the number of users rising across Europe (including in France), the aim of this issue of Tendances is to review what is known about the subject, notably what is available, who are the users, how these products are being taken, health consequences and questions about the relevant French legislation.
Emmanuel Lahaie, Magali Martinez, Agnès Cadet-Taïrou
Download the PDF file (301 Ko)
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.